Artificial nucleic acid molecules for improved protein expression
AssigneeCureVac AG
InventorsAndreas Thess, Thomas Schlake, Stefanie Grund
Life of this patent
Estimating the term…
Loading patent…
AssigneeCureVac AG
InventorsAndreas Thess, Thomas Schlake, Stefanie Grund
Estimating the term…
The invention relates to an artificial nucleic acid molecule comprising an open reading frame and a 3′-UTR comprising at least one poly(A) sequence or a polyadenylation signal. The invention further relates to a vector comprising the artificial nucleic acid molecule comprising an open reading frame and a 3′-UTR comprising at least one poly(A) sequence or a polyadenylation signal, to a cell comprising the artificial nucleic acid molecule or the vector, to a pharmaceutical composition comprising the artificial nucleic acid molecule or the vector and to a kit comprising the artificial nucleic acid molecule, the vector and/or the pharmaceutical composition. The invention also relates to a method for increasing protein production from an artificial nucleic acid molecule and to the use of a 3′-UTR for a method for increasing protein production from an artificial nucleic acid molecule. Moreover, the invention concerns the use of the artificial nucleic acid molecule, the vector, the kit or the pharmaceutical composition as a medicament, as a vaccine or in gene therapy.
A method for treating or preventing an infectious disease, the method comprising administering an RNA molecule comprising:
Dependencies are inferred from the claim text.